Deva Holding AS Cash Flow Conversion Efficiency

Latest as of September 2025: 0.058x

Deva Holding AS cash flow conversion efficiency. Based on the latest financial reports, Deva Holding AS (DEVA) has a cash flow conversion efficiency ratio of 0.058x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (TL1.53 Billion ≈ $34.34 Million USD) by net assets (TL26.48 Billion ≈ $593.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Deva Holding AS (2005–2024)

Cash flow conversion efficiency of Deva Holding AS from 2005 to 2024. This chart illustrates how Deva Holding AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DEVA stock price for real-time trading data and today's change.

Deva Holding AS Cash Flow Conversion Ratio Explained

Deva Holding AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Deva Holding AS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Deva Holding AS ranked by their cash flow conversion efficiency. Also see market cap of Deva Holding AS for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Bourrelier Group SA
PA:ALBOU
0.072x
BK Technologies Inc
NYSE MKT:BKTI
0.067x
M3-Brigade Acquisition V Corp. Class A Ordinary shares
NASDAQ:MBAV
-0.001x
Launch Two Acquisition Corp. Class A Ordinary Shares
NASDAQ:LPBB
0.000x
Bsm Chemical Co Ltd
SHE:300796
0.056x
WONIK Materials Co.Ltd
KQ:104830
0.029x
Guangdong Dcenti Auto-Parts Stock Ltd Co
SHG:603335
0.088x
Biofarm Bucure
RO:BIO
0.052x

Annual Cash Flow Conversion Efficiency for Deva Holding AS (2005–2024)

The table below shows the annual cash flow conversion efficiency of Deva Holding AS from 2005 to 2024. Review Deva Holding AS free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 TL20.81 Billion
≈ $466.11 Million
TL5.07 Billion
≈ $113.50 Million
0.243x -27.39%
2023-12-31 TL21.34 Billion
≈ $478.04 Million
TL7.16 Billion
≈ $160.30 Million
0.335x +61.80%
2022-12-31 TL3.94 Billion
≈ $88.17 Million
TL815.91 Million
≈ $18.27 Million
0.207x -54.69%
2021-12-31 TL2.73 Billion
≈ $61.10 Million
TL1.25 Billion
≈ $27.95 Million
0.457x +15.74%
2020-12-31 TL1.63 Billion
≈ $36.61 Million
TL645.98 Million
≈ $14.47 Million
0.395x -7.66%
2019-12-31 TL1.03 Billion
≈ $23.09 Million
TL441.24 Million
≈ $9.88 Million
0.428x +143.91%
2018-12-31 TL746.41 Million
≈ $16.72 Million
TL130.98 Million
≈ $2.93 Million
0.175x -4.20%
2017-12-31 TL605.09 Million
≈ $13.55 Million
TL110.84 Million
≈ $2.48 Million
0.183x -49.88%
2016-12-31 TL512.85 Million
≈ $11.49 Million
TL187.44 Million
≈ $4.20 Million
0.365x +86.96%
2015-12-31 TL453.11 Million
≈ $10.15 Million
TL88.58 Million
≈ $1.98 Million
0.195x +56.38%
2014-12-31 TL411.91 Million
≈ $9.23 Million
TL51.49 Million
≈ $1.15 Million
0.125x +0.69%
2013-12-31 TL403.05 Million
≈ $9.03 Million
TL50.04 Million
≈ $1.12 Million
0.124x +618.95%
2012-12-31 TL378.63 Million
≈ $8.48 Million
TL6.54 Million
≈ $146.43K
0.017x -67.04%
2005-12-31 TL114.50 Million
≈ $2.56 Million
TL6.00 Million
≈ $134.34K
0.052x --

About Deva Holding AS

IS:DEVA Turkey Drug Manufacturers - Specialty & Generic
Market Cap
$310.23 Million
TL13.85 Billion TRY
Market Cap Rank
#14347 Global
#104 in Turkey
Share Price
TL69.25
Change (1 day)
-1.77%
52-Week Range
TL59.00 - TL105.10
All Time High
TL105.10
About

Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also provides products in the areas of urogenital system and sex hormones, blood and … Read more